SCEW: a Microsoft Excel add-in for easy creation of survival curves

Using macros in microsoft excel to facilitate cleaning of research data

Background: Retrospective chart review studies may be delayed by inability to export clean clinical data from an electronic medical record (EMR) or data repository. Macros are pre-programmed procedures that can be used in Microsoft Excel to help streamline the process of cleaning clinical datasets.

Objectives: To demonstrate how macros may be useful for researchers at community hospitals and smaller academic health centers that lack informatics support.

Methods: Using an intrinsic function of our institution’s EMR, vital signs and lab results from 20 individual hospitalizations were exported to a spreadsheet. Two macros were developed to sort through these datasets and output them into a specified format. The speed of macro-assisted data cleaning was compared to manual transcription.

Results: Time spent on data cleaning was significantly reduced when using macro-assisted sorting compared to the manual approach for both vital signs (46.5 seconds versus 12.3 minutes per record, a 94% reduction; P < 0.001) and labs (13.7 seconds versus 2.6 minutes per record, a 91% reduction; P < 0.001).

Conclusions:Macros offer a flexible and efficient tool for cleaning large sets of clinical data, particularly when an institution lacks informatics support or EMR functionality to export clinical data in an analysis-ready format.

Eptifibatide in post-infarction angina patients who refused intervention: Ajmer postmyocardial infarction angina eptifibatide research (AJMER) study: a pilot study

BACKGROUND

Early intervention is certainly a preferred strategy over conservative management in patients with post-infarction angina (PIA). But at times, it may not be feasible to intervene, especially if patient refuses for intervention. In a pilot study, we analyzed whether the addition of eptifibatide to intensified antianginal therapy would be of added benefit, in patients with PIA not willing to undergo intervention.

METHODS

A total of 461 patients with PIA who refused intervention were randomized in a 1:1 manner to receive either eptifibatide along with intensification of antianginal therapy (group A; n = 229) or intensified antianginal therapy alone (group B; n = 232). The primary endpoints were composite of all-cause death and nonfatal myocardial infarction at 30 days.

RESULTS

Primary composite endpoint did not differ between the two groups (16.2% vs. 18.9% in group A and group B, odds ratio [OR], 0.82; 95% CI, 0.5-1.30; P-value = 0.43). Significant earlier relief of angina (complete relief of angina within 12 h: 76% of patients in group A vs. 40.5% in group B; P-value <0.0001) was achieved in group A compared to group B. Although on Bleeding Academic Research Consortium (BARC) scale, type 1 and 2 bleeding was higher in group A (OR, 3.18; 95% CI, 1.76-5.74; P-value = 0.0001), the more serious (composite of type 3 and 5) bleeds did not show any difference (OR, 1.73; 95% CI, 0.7-4.08; P-value = 0.21).

CONCLUSION

In patients with PIA who refused intervention, eptifibatide infusion resulted in earlier relief of angina albeit at the cost of increased non-life-threatening bleeding. Further, this effect was achieved in significantly higher number of patients receiving eptifibatide infusion when compared to patients not receiving it. Primary composite endpoints, however, did not differ in two groups, but being a pilot study, this needs to be confirmed by larger study of adequate sample size.

Ca analysis: an Excel based program for the analysis of intracellular calcium transients including multiple, simultaneous regression analysis

Here I present an Excel based program for the analysis of intracellular Ca transients recorded using fluorescent indicators. The program can perform all the necessary steps which convert recorded raw voltage changes into meaningful physiological information. The program performs two fundamental processes. (1) It can prepare the raw signal by several methods. (2) It can then be used to analyze the prepared data to provide information such as absolute intracellular Ca levels. Also, the rates of change of Ca can be measured using multiple, simultaneous regression analysis. I demonstrate that this program performs equally well as commercially available software, but has numerous advantages, namely creating a simplified, self-contained analysis workflow.

High-throughput and longitudinal analysis of aging and senescent decline in Caenorhabditis elegans

Caenorhabditis elegans is becoming a multipurpose tool for genetic and chemical compound screening approaches aiming to identify and target the molecular mechanisms underlying senescent decline, aging, and associated pathologies. In this chapter, we describe specialized methods that have been developed to facilitate such screening strategies using C. elegans. The first section provides detailed procedures for the assessment of lifespan parameters on liquid growth media that are typically used for rearing nematodes. In the second section, we consider methodologies optimized for high-throughput survival analysis, applicable to large-scale chemical compound or genetic screening ventures. Finally, we discuss recently developed microfluidics tools for the noninvasive monitoring of behavioral and physiological traits in longitudinal studies of aging and senescent decline.

Assessing aging and senescent decline in Caenorhabditis elegans: cohort survival analysis

The nematode Caenorhabditis elegans provides a versatile and expedient platform for the genetic and molecular dissection of mechanisms underlying senescent decline and aging. Indeed, pioneering studies in this organism revealed the first genes and pathways directly influencing lifespan. In this chapter, we present routine, mainstream methods, developed for monitoring aging and senescent decline in C. elegans. These procedures allow the assessment of lifespan parameters on solid growth media that are typically used for rearing nematodes.

PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel

This study presents PKSolver, a freely available menu-driven add-in program for Microsoft Excel written in Visual Basic for Applications (VBA), for solving basic problems in pharmacokinetic (PK) and pharmacodynamic (PD) data analysis. The program provides a range of modules for PK and PD analysis including noncompartmental analysis (NCA), compartmental analysis (CA), and pharmacodynamic modeling. Two special built-in modules, multiple absorption sites (MAS) and enterohepatic circulation (EHC), were developed for fitting the double-peak concentration-time profile based on the classical one-compartment model. In addition, twenty frequently used pharmacokinetic functions were encoded as a macro and can be directly accessed in an Excel spreadsheet. To evaluate the program, a detailed comparison of modeling PK data using PKSolver and professional PK/PD software package WinNonlin and Scientist was performed. The results showed that the parameters estimated with PKSolver were satisfactory. In conclusion, the PKSolver simplified the PK and PD data analysis process and its output could be generated in Microsoft Word in the form of an integrated report. The program provides pharmacokinetic researchers with a fast and easy-to-use tool for routine and basic PK and PD data analysis with a more user-friendly interface.